Overview

• AdFalciVax is an indigenously developed recombinant chimeric multi-stage vaccine targeting Plasmodium falciparum to prevent infection and curb community transmission.
• ICMR has opened its EoI until August 17 for non-exclusive technology transfer partnerships, offering technical support through its institutes with no financial liability for the council.
• Under the agreement, selected partners will handle all regulatory approvals and pay a 2% royalty on net sales, with ICMR retaining sole ownership of the underlying technology and IP.
• The vaccine’s development roadmap spans at least seven years across four stages, each including a six-month buffer to cover preclinical work, regulatory filings, clinical trials and scale-up.
• India accounts for half of the WHO South-East Asia Region’s malaria cases, and this initiative aligns with the nation’s Make in India mandate to bolster domestic R&D.